Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
It appears to modulate the immune response by influencing cytokine activity and suppressing pro-inflammatory signaling
Klausen MK, Thomsen M, Wortwein G, et al
Some practitioners combine phentermine with a GLP-1 agonist
These drugs are whats known as GLP-1s, just like Ozempic, the popular diabetes medication that kicked off a revolution in the pharmaceutical industry and inspired as many as 12% of people in the U.S
US$ 28.83
US$ 28.89
US$ 26.18
US$ 22.50
US$ 24.37
US$ 28.01
